May 16 News: Resveratrol, Myxo Ring, ALSYNC, AF Ablation, More

The heartwire team

Disclosures

May 16, 2014

This feature requires the newest version of Flash. You can download it here.

For the week ending May 16, 2014, we discuss the following top cardiology news from heartwire:

Resveratrol Does Not Reduce CVD Risk, Prolong Life

Myxo Ring Dispute: Tale of Two Studies Puts IRB in Hot Seat

ALSYNC: LV Endocardial Pacing Could Help in CRT Nonresponse

Bias Among EPs Who Refer AF Patients for Ablation

And also, in brief:

FDA Review Finds No Increased Risk of MI With Dabigatran (Pradaxa)

FDA Approves Vorapaxar (Zontivity) to Cut MI, Stroke Risk

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....